GlassScriptPhysician profile
Thomas Cascino
NPI 1679839807
$39,080.89
in general payments reported to CMS, 2019-2025
11 companies · $11K in 2025
The $11K reported for 2025 was more than what 78% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,565 · 2020: $300 · 2021: $550 · 2022: $454 · 2023: $1,183 · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $5,174 · Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,304.75 |
| Travel and Lodging | $5,174.07 |
| Food and Beverage | $2,733.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20,449.07 | 2019-2025 | Winrevair |
| Medtronic Vascular, INC. | $8,814.53 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $3,971.16 | 2023-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $2,166.61 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $1,774.32 | 2024-2025 | Impella |
| Impulse Dynamics (USA) INC. | $1,120.60 | 2025 | Optimizer |
| Cvrx, INC. | $319.29 | 2025 | Barostim Neo System |
| United Therapeutics Corporation | $188.27 | 2022-2024 | Tyvaso, Remodulin, Orenitram |
| Endotronix, INC. | $185.61 | 2023-2024 | Cordella Pulomonary Artery Pressure Sensor |
| Edwards Lifesciences Corporation | $91.43 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cascino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.